Global Payments–The company earned 96 cents per share, excluding certain items, for its third quarter, beating estimates by a penny. The credit card processor did raise its yearly forecast, despite last quarter's increase in interest expenses.
Align Technology–The maker of the Invisalign orthodontic system said the International Trade Commission has made an initial determination that rival ClearCorrect violated five of Align's patents.
GameStop–Bank of America/Merrill Lynch upgraded the video game retailer's stock to "buy" from "neutral", saying the stock's recent slide improves its risk/reward profile, and that GameStop will benefit from the new versions of game consoles hitting the market.
Boeing–Boeing is considering buying Mercury Systems, a supplier of digital signal and image processing systems to Boeing and other defense contractors. Mercury currently has a market value of about $440 million.
GrubHub (GRUB) – The online food delivery service begins trading today on the New York Stock Exchange after pricing its IPO at $26 per share. That was above the expected range of $23 to $25.
AIG–The insurance big New York State regulators to stop an investigation of insurance marketing by a unit no longer owned by AIG. MetLife bought American Life Insurance, as well as another AIG unit, in 2010.
Coca-Cola –Coke is being criticized once again by activist investor Wintergreen Advisors, which owns more than 2.5 million shares. CEO David Winters told CNBC's "Closing Bell" that the Coke's stock buyback plan has "been hijacked" by the company, and repeated his criticism of Coke's management compensation plan.
General Motors–The auto giant has boosted discounts on its full-size Chevy Silverado pickup truck, after rival Chrysler Ram 1500 outsold the Silverado in March. Separately, the National Highway Traffic Safety Administration said it has been receiving documents from the automaker on its controversial ignition switch recall, after issuing a special order requiring GM to produce documents and answer questions.
Mylan–The pharmaceutical behemoth may buy Swedish rival Meda, according to the Financial Times, a combination that would create a $23 billion company. In a separate story, Mylan is suing Celgene, to stop that company's efforts to prevent Mylan from marketing generic version of two Celgene drugs, Revlimid and Thalomid.
Brown-Forman–The company may be mulling a bid for spirits producer Remy Cointreau, according to European traders citing a report on the "Betaville" blog.
Citigroup–Senior executive Gene McQuade has reversed retirement plans and instead will lead Citi's efforts to get Fed approval for increasing stock buybacks and dividends. McQuade has been serving as CEO of the company's U.S. operating subsidiary, Citibank.
Potbelly–William Blair upgraded the sandwich chain's shares to "outperform" from "market perform."
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com